Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 23 studies | 28% ± 14% | |
connective tissue cell | 6 studies | 23% ± 8% | |
adventitial cell | 5 studies | 47% ± 14% |
Insufficient scRNA-seq data for expression of SCARA5 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 88% | 5984.60 | 851 / 966 | 56% | 4.79 | 296 / 527 |
bladder | 100% | 14474.62 | 21 / 21 | 43% | 2.69 | 219 / 504 |
stomach | 86% | 4257.59 | 307 / 359 | 54% | 2.99 | 154 / 286 |
breast | 92% | 5698.80 | 423 / 459 | 44% | 2.81 | 490 / 1118 |
esophagus | 88% | 8278.03 | 1269 / 1445 | 40% | 3.85 | 73 / 183 |
thymus | 83% | 4311.70 | 545 / 653 | 35% | 2.86 | 213 / 605 |
lung | 74% | 3773.94 | 427 / 578 | 45% | 3.25 | 515 / 1155 |
skin | 64% | 3620.48 | 1152 / 1809 | 42% | 3.57 | 200 / 472 |
adipose | 98% | 11380.11 | 1183 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 92% | 7584.16 | 1227 / 1335 | 0% | 0 | 0 / 0 |
heart | 90% | 7767.57 | 776 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 69% | 5.40 | 20 / 29 |
prostate | 30% | 1427.03 | 74 / 245 | 28% | 0.98 | 139 / 502 |
muscle | 53% | 1293.98 | 427 / 803 | 0% | 0 | 0 / 0 |
ovary | 43% | 1734.46 | 78 / 180 | 10% | 0.45 | 42 / 430 |
pancreas | 2% | 31.24 | 7 / 328 | 49% | 5.25 | 87 / 178 |
adrenal gland | 9% | 249.98 | 24 / 258 | 37% | 4.46 | 86 / 230 |
uterus | 24% | 807.16 | 40 / 170 | 20% | 1.60 | 92 / 459 |
brain | 0% | 9.99 | 11 / 2642 | 29% | 1.59 | 204 / 705 |
tonsil | 0% | 0 | 0 / 0 | 24% | 0.85 | 11 / 45 |
eye | 0% | 0 | 0 / 0 | 20% | 0.89 | 16 / 80 |
liver | 0% | 6.48 | 1 / 226 | 17% | 0.92 | 71 / 406 |
kidney | 3% | 123.66 | 3 / 89 | 12% | 0.53 | 110 / 901 |
spleen | 2% | 40.74 | 6 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 8.08 | 4 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0034755 | Biological process | iron ion transmembrane transport |
GO_0070207 | Biological process | protein homotrimerization |
GO_0006879 | Biological process | intracellular iron ion homeostasis |
GO_0006897 | Biological process | endocytosis |
GO_0034605 | Biological process | cellular response to heat |
GO_0009986 | Cellular component | cell surface |
GO_0005886 | Cellular component | plasma membrane |
GO_0070287 | Molecular function | ferritin receptor activity |
Gene name | SCARA5 |
Protein name | Scavenger receptor class A member 5 (Scavenger receptor hlg) |
Synonyms | UNQ2938/PRO28700 |
Description | FUNCTION: Ferritin receptor that mediates non-transferrin-dependent delivery of iron. Mediates cellular uptake of ferritin-bound iron by stimulating ferritin endocytosis from the cell surface with consequent iron delivery within the cell. Delivery of iron to cells by ferritin is required for the development of specific cell types, suggesting the existence of cell type-specific mechanisms of iron traffic in organogenesis, which alternatively utilize transferrin or non-transferrin iron delivery pathways. Ferritin mediates iron uptake in capsule cells of the developing kidney. Preferentially binds ferritin light chain (FTL) compared to heavy chain (FTH1). . |
Accessions | ENST00000518030.1 [Q6ZMJ2-3] ENST00000354914.8 [Q6ZMJ2-1] ENST00000380385.6 [Q6ZMJ2-4] Q6ZMJ2 ENST00000524352.5 [Q6ZMJ2-2] |